GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors

Most breast cancers at diagnosis are estrogen receptor (ER)-positive and depend on estrogen for growth and survival. Blocking estrogen biosynthesis by aromatase inhibitors (AI) has therefore become a first-line endocrine therapy for post-menopausal women with ER-positive breast cancers. Despite prov...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Morandi, Andrea, Martin, Lesley-Ann, Gao, Qiong, Pancholi, Sunil, Mackay, Alan, Robertson, David, Zvelebil, Marketa, Dowsett, Mitch, Plaza-Menacho, Ivan, Isacke, Clare M.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3686594/
https://ncbi.nlm.nih.gov/pubmed/23650283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-4265
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares